Health Care Delivery

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

Kerry Rogers, MD, breaks down the clinical and lifestyle factors that drive frontline treatment selection between BTK inhibitors and venetoclax regimens.

Jonathan Wrathall, PhD, explains that his 2 studies found social needs and insurance type strongly predicted food insecurity.

Private equity reshapes care—new evidence links staffing cuts to patient safety risks; ACP urges regulatory oversight to defend clinical autonomy.

Pharmacists need better support to manage emotional strain tied to patient suffering, treatment costs, and care decisions, says Karen Fancher, PharmD, BCOP.

US health care faces massive shifts: rising ACA deductibles, federal health leadership shakeups, and major care gaps in women's health and dermatology.

Yet Khor, MD, PhD, discusses ILD care disparities, telehealth, trial awareness, and shared care strategies.

Mark Metersky, MD, discussed heterogeneity, pathogens, and precision approaches in community-acquired pneumonia care.

A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.

Jamie R. Felzer, MD, discussed emerging vaccine strategies, preventive care, and translating evolving evidence into pulmonary practice at ATS 2026.

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know about managing infections and CRS.

The Trump administration fired USPSTF leaders, sparking concerns over the future of ACA-mandated free medical screenings and preventive care.

ACA enrollment drops 21.5% in 2026 after enhanced subsidies end. Deductibles hit record $3786 as enrollees shift to high-deductible bronze plans.

TrumpRx will include more than 600 generic medications; experts say the platform’s impact on high-cost specialty drug affordability may be limited.

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.

Jerry A. Krishnan, MD, PhD, discusses NIH RECOVER findings on long COVID, pulmonary complications, and immune dysfunction at ATS 2026.

Diana Verrilli, MS, of Navista breaks down the regulatory, payer, and cybersecurity pressures threatening community oncology practices—and maps a path forward.

Chad Hochberg, MD, discussed how ICU learning health systems and predictive tools may improve critical care delivery.

Investigators found major variation in prior authorization rules across commercial insurers, highlighting limited standardization and transparency.

A new review links coexisting sleep apnea and diabetes to higher stroke risk, poorer recovery, and greater vascular damage.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”

PASSAGE trial data showed tezepelumab reduced asthma exacerbations in diverse and underrepresented patient populations, noted Njira L. Lugogo, MD.

ATS 2026 findings highlighted bleeding risks and hemodynamic responses with sotatercept in CTD-associated pulmonary arterial hypertension (PAH).

Efficacy and safety top the list for patients and physicians making R/R CLL treatment decisions, yet fewer than 1 in 3 patients felt their doctor fully answered their questions.